Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
## Overview\nBacillus coagulans is a spore-forming, lactic acid-producing probiotic bacterium used as an oral live microbial therapeutic or probiotic ingredient. In the provided clinical and publication context, it appears as live tablets, powder, and food-based formulations and is being studied across gastrointestinal and supportive-care settings including constipation, recovery of intestinal function after surgery, oral mucositis prophylaxis after hematopoietic stem cell transplantation, Helicobacter pylori-related disease, dental caries, and respiratory illness in children with asthma. Its proposed mechanism is not a single receptor-based pharmacology but modulation of the intestinal or oral microbiome and host mucosal immune environment, including suppression of potentially harmful bacteria such as Enterobacteriaceae or mutans streptococci, promotion of short-chain-fatty-acid-associated commensals such as Lachnospiraceae in some settings, and downstream effects on inflammation and barrier or ecosystem function. The exact biological properties can be strain-specific, so findings for one strain such as SANK 70258 should not be assumed to apply identically to all Bacillus coagulans products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacillus coagulans.